Interpretation of the Drug Post-marketing Intensive Surveillance Policy in China

Ting Cai,Lei Yan,Shusen Liu,Siyan Zhan
DOI: https://doi.org/10.19960/j.cnki.issn1005-0698.2017.05.001
2017-01-01
Abstract:To strenghthen the drug post-marketing surveillance system and ensure the drug safety,the China Food and Drug Administration (CFDA) introduced a policy of drug post-marketing intensive surveillance and its related work guideline in 2013.This guideline regulated the property,content,responsibility,procedure and criterion of the intensive surveillance to direct pharmaceutical companies to carry out the work and implement the policy.Since the policy was on its initial stage and the understanding of the regulation was discrepant,learning about the content of the guideline and discussing the potential problems could be helpful to achieve the objective and expectation of the intensive surveillance.
What problem does this paper attempt to address?